Proteomic Profiling of Age-Related Proteins Following Extracorporeal Apheresis

Abstract

Lipoprotein apheresis (LA) is often the last option to adequately reduce lipoproteins in patients with familial hypercholesterolemia and lipoprotein (a) hyperlipidemia. Characterized by mild side effects, it is now the most effective method of preventing major cardiovascular events (CVEs). This benefit is due not only to the lowering of lipoprotein levels, but probably also to many other pleiotropic effects that have been extensively described in the literature. These include the reduction of inflammatory signaling substances, fibrinogen, plasminogen or components of the oxidative stress response. Here, we performed a proteomic analysis of 12 patients treated with therapeutic apheresis using two different pore size filters to quantify the effect on age-related plasma proteins. This study showed that important proteins such as α-2-macroglobulin, apolipoprotein C-III, complement C1s subcomponent, C4b-binding protein alpha chain, CD5 antigen-like and pregnancy zone protein, whose role in numerous aging processes has been well described, were significantly reduced by apheresis treatment. We conclude that therapeutic apheresis may be a promising approach to reduce these age-related proteins and that these treatments may become an essential part of managing cardiovascular risk in an aging population.

Keywords

extracorporal apheresis - proteomic analysis - aging

Publication History

Received: 24 January 2025

Accepted after revision: 10 March 2025

Article published online:
15 April 2025

• References

• 1 Zhao D, Wang Y, Wong ND. et al. Impact of aging on cardiovascular diseases: from chronological observation to biological insights: JACC Fam Ser . JACC Asia 2024; 4: 345-358
• 2 Baird GS, Nelson SK, Keeney TR. et al. Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol 2012; 180: 446-456
• 3 Ignjatovic V, Lai C, Summerhayes R. et al. Age-related differences in plasma proteins: how plasma proteins change from neonates to adults. PloS One 2011; 6: e17213
• 4 Moaddel R, Ubaida-Mohien C, Tanaka T. et al. Proteomics in aging research: a roadmap to clinical, translational research. Aging Cell 2021; 20: e13325
• 5 Oh HS, Rutledge J, Nachun D. et al. Organ aging signatures in the plasma proteome track health and disease. Nature 2023; 624: 164-172
• 6 Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. Nat Rev Genet 2022; 23: 715-727
• 7 Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol 2012; 22: R741-R752
• 8 Julius U, Siegert G, Kostka H. et al. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl 2015; 18: 95-102
• 9 Kopprasch S, Bornstein SR, Bergmann S. et al. Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI). Atheroscler Suppl 2017; 30: 115-121
• 10 Otto C, Geiss HC, Empen K. et al. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 2004; 174: 151-156
• 11 Tselmin S, Schmitz G, Julius U. et al. Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009; 10: 27-33
• 12 Yin X, Takov K, Straube R. et al. Precision medicine approach for cardiometabolic risk factors in therapeutic apheresis. Horm Metab Res 2022; 54: 238-249
• 13 Smyth GK. limma: Linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (eds). Bioinformatics and computational biology solutions using R and bioconductor. New York, NY: Springer; 2005: 397-420
• 14 [Anonymous] 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205
• 15 Akoumianakis I, Zvintzou E, Kypreos K. et al. ANGPTL3 and apolipoprotein C-III as novel lipid-lowering targets. Curr Atheroscler Rep 2021; 23: 20
• 16 Zewinger S, Reiser J, Jankowski V. et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 2020; 21: 30-41
• 17 Jia G, Aroor AR, Jia C. et al. Endothelial cell senescence in aging-related vascular dysfunction. Biochim Biophys Acta Mol Basis Dis 2019; 1865: 1802-1809
• 18 Martinelli N, Baroni M, Castagna A. et al. Apolipoprotein C-III strongly correlates with activated factor VII–anti-thrombin complex: an additional link between plasma lipids and coagulation. Thromb Haemost 2019; 119: 192-202
• 19 Bergmark BA, Marston NA, Prohaska TA. et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Eng J Med 2024; 390: 1770-1780
• 20 Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep 2023; 25: 701-709
• 21 Bornfeldt KE. Apolipoprotein C3: form begets function. J Lipid Res 2024; 65: 100475
• 22 Marcovina SM, Zoppo A, Viganó-D'Angelo S. et al. Determination of serum levels of complement component C4b-binding protein: influence of age and inflammation. Int J Clin Lab Res 1991; 21: 171-175
• 23 Taylor F, Chang A, Ferrell G. et al. C4b-binding protein exacerbates the host response to escherichia coli. Blood 1991; 78: 357-363
• 24 Westein E, Denis CV, Bouma BN. et al. The α-chains of C4b-binding protein mediate complex formation with low density lipoprotein receptor-related protein. J Biol Chem 2002; 277: 2511-2516
• 25 Dikhoff MJ, ter Weeme M, Vonk AB. et al. C4b-binding protein deposition is induced in diseased aortic heart valves, coinciding with C3d. J Heart Valve Dis 2015; 24: 451-456
• 26 Sánchez-Pernaute O, Esparza-Gordillo J, Largo R. et al. Expression of the peptide C4b-binding protein beta in the arthritic joint. Ann Rheum Dis 2006; 65: 1279-1285
• 27 Trouw LA, Okroj M, Kupreishvili K. et al. C4b-binding protein is present in affected areas of myocardial infarction during the acute inflammatory phase and covers a larger area than C3. PloS one 2008; 3: e2886
• 28 Ma H, Li R, Zhang Z. et al. mRNA level of alpha-2-macroglobulin as an aging biomarker of human fibroblasts in culture. Exp Gerontol 2004; 39: 415-421
• 29 Kosmadakis G. Rheopheresis: a narrative review. Int J Artificial Organs 2022; 45: 445-454
• 30 Klingel R, Fassbender C, Fassbender T. et al. Rheopheresis: rheologic, functional, and structural aspects. Therap Apheresis 2000; 4: 348-357
• 31 Hu Z, Zhang M, Fan J. et al. High-level secretion of pregnancy zone protein is a novel biomarker of DNA damage-induced senescence and promotes spontaneous senescence. J Proteome Res 2023; 22: 3570-3579
• 32 Finch S, Shoemark A, Dicker AJ. et al. Pregnancy zone protein is associated with airway infection, neutrophil extracellular trap formation, and disease severity in bronchiectasis. Am J Respir Crit Care Med 2019; 200: 992-1001
• 33 Sanjurjo L, Aran G, Roher N. et al. AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease. J Leukocyte Biol 2015; 98: 173-184
• 34 Castelblanco E, Sarrias MR, Betriu À. et al. Circulating CD5L is associated with cardiovascular events and all-cause mortality in individuals with chronic kidney disease. Aging (Albany NY) 2021; 13: 22690-22709
• 35 Sinzinger H, Steiner S, Derfler K. Pleiotropic effects of regular lipoprotein-apheresis. Atheroscler Suppl 2017; 30: 122-127
• 36 Yuasa Y, Osaki T, Makino H. et al. Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis. Therap Apheresis Dialysis 2014; 18: 93-102
• 37 Marlęga-Linert J, Gąsecka A, van der Pol E. et al. Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a). Sci Rep 2024; 14: 2762